Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-02-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司拟非公开发行股份构成管理层收购所涉及的金宇生物技术股份有限公司股东全部权益价值资产评估报告
Regulatory Filings
2023-02-07 Chinese
北京博星证券投资顾问有限公司关于金宇生物技术股份有限公司详式权益变动报告书之财务顾问核查意见
Regulatory Filings
2023-02-07 Chinese
金宇生物技术股份有限公司详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled '详式权益变动报告书' which translates to 'Detailed Equity Change Report'. It is issued by 金宇生物技术股份有限公司 and details a significant change in shareholding involving a management buyout and subscription of new shares by insiders. The document includes extensive information about the shareholders, their shareholding percentages before and after the transaction, the purpose of the equity change, legal references to Chinese securities laws and regulations, and financial data of the controlling entities. It is a comprehensive report on a significant shareholding change, consistent with a Major Shareholding Notification filing. The document is lengthy (15,000 characters) and contains detailed substantive information, not just an announcement or certification. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2023-02-07 Chinese
金宇生物技术股份有限公司关于非公开发行A股股票预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding a non-public issuance of A shares by the company. It mentions the board meeting approval and references a detailed issuance plan disclosed on the stock exchange website. The document explicitly states it is a "提示性公告" (a prompt or indicative announcement) about the issuance plan, not the plan itself or detailed financial data. The length is only 545 characters, indicating it is a brief announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), which covers updates on fundraising and capital structure changes.
2023-02-07 Chinese
金宇生物技术股份有限公司关于无需编制前次募集资金使用情况报告的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the non-requirement to prepare a report on the use of previously raised funds. It references regulatory rules from the China Securities Regulatory Commission about fundraising and reporting requirements. The document is short (1051 characters) and serves as a formal notice explaining that due to the time elapsed since the last fundraising, no new report on prior fundraising usage is needed. It does not contain financial statements or detailed financial data, nor is it a full report. This fits the description of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-02-07 Chinese
金宇生物技术股份有限公司独立董事关于公司第十一届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion report from the independent directors of a company regarding the company's non-public issuance of A shares in 2023. It discusses compliance with laws and regulations, fairness of the transaction, related party transactions, and management buyout aspects. The document is detailed and addresses multiple agenda items related to the issuance and associated shareholder meeting matters. It is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a formal independent opinion related to board/management matters and shareholder meeting agenda items, specifically concerning management and board decisions on financing and related transactions. Therefore, it fits best under Board/Management Information (MANG). The document length is under 5,000 characters but contains substantive independent opinions on board matters, not just an announcement or notice, so it is not RPA or RNS. Hence, the classification is MANG with high confidence.
2023-02-07 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.